Core Viewpoint - The company, Huahai Pharmaceutical, has announced the initiation of Phase III clinical trials for HB0025, a novel PD-L1/VEGF dual-specific fusion protein aimed at treating squamous and non-squamous non-small cell lung cancer [1][2]. Group 1: Clinical Development - The company’s subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., will officially start the Phase III clinical trial for HB0025 after discussions with the National Medical Products Administration [1]. - HB0025 is designed to target both PD-L1 and VEGF pathways, enhancing anti-tumor mechanisms through dual action on immune evasion and tumor angiogenesis [1][2]. - The Phase III trials will include two confirmatory studies, which are expected to provide new first-line treatment options for advanced non-small cell lung cancer patients, regardless of PD-L1 expression levels [2]. Group 2: Competitive Landscape - Currently, other PD-1/VEGF dual antibodies, such as Ivosidenib by Kangfang Biotech and PM8002 by BMS, have entered clinical Phase III, indicating a competitive market for dual-target therapies [2]. - The promising Phase II clinical data for HB0025, presented at the 2025 ESMO conference, showed good objective response rates and disease control rates, particularly in PD-L1 negative populations [2]. Group 3: Financial Investment - The company has invested approximately RMB 32.597 million in the research and development of the HB0025 project to date [3].

Core Viewpoint - The company is actively engaged in the research and development of innovative drugs and biosimilars through its subsidiaries, with several products nearing market readiness [2]. Group 1: Product Development - Bevacizumab has obtained its drug registration certificate in November 2024, and will commence production and sales [2]. - Rituximab and Dexamethasone are expected to complete clinical studies and submit drug registration applications by November 2024 and December 2025, respectively, with their applications already accepted [2]. - Other products, including Adalimumab, Trastuzumab, Ipilimumab, and several monoclonal antibodies and fusion proteins, have received clinical approval and are undergoing related clinical studies, contributing to the company's new profit growth points and product portfolio enhancement [2].

Core Viewpoint - The company emphasizes innovation in its research and development strategy, focusing on innovative drugs, improved new drugs, and generic drugs with technical barriers, while gradually reducing investment in ordinary generic drugs [1] Group 1: R&D Focus - The company has six ongoing innovative drug R&D projects, with the core project LH-1801 (SGLT-2 inhibitor) currently in the Ⅲ phase clinical trial, expected to unblind in Q1 2026 [1] - LH-1801 demonstrates differentiated advantages in controlling glycosylated hemoglobin and offers benefits for heart failure and kidney protection, indicating a broad future market potential [1] - The company is also developing LH-1802 for acute myeloid leukemia, which is in clinical trial stages, and LH-1901 for chronic obstructive pulmonary disease, which has initiated phase I clinical trials [1] Group 2: Collaborations and Achievements - The company collaborates with renowned research institutions and universities, including the Shanghai Institute of Pharmaceutical Industry, China Pharmaceutical University, and Zhejiang University, through its academician and doctoral workstations [1] - As of 2025, the company has obtained 13 production approvals and 2 clinical approvals, being one of the two companies to pass the consistency evaluation for methanesulfonic acid phenylephrine injection (1ml: 10mg) [1] - The company is one of three manufacturers in China for the market of benazepril potassium tablets and the first nationwide company to pass the consistency evaluation for hydrochloride quetiapine tablets [1]

Investment Rating - The report initiates coverage with an "Accumulate" rating for the company [3][9]. Core Insights - The company has successfully transitioned to innovative drug development, particularly in the ADC (Antibody-Drug Conjugate) sector, highlighted by a significant global collaboration with BMS worth $8.4 billion for the EGFR/HER3 dual-target ADC, which positions the company for accelerated growth [6][8]. - The core product, iza-bren, is advancing through clinical trials and is expected to enter commercialization soon, with a potential market approval in 2026 for nasopharyngeal carcinoma [8][41]. - The company has established four major technology platforms that support a diverse pipeline of innovative drug candidates, enhancing its competitive edge in the oncology market [37][41]. Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 2,211 million yuan, with a significant year-on-year decline of 62% due to increased R&D investments [7]. - The company anticipates net losses of 599 million yuan in 2025, with further losses projected for 2026 and 2027 [9]. - The gross margin is expected to decrease from 89% in 2025 to 85.6% by 2027, reflecting the evolving product mix as innovative drugs gain market traction [7][10]. Pipeline Analysis - The company is focusing on the clinical development of iza-bren, with multiple indications being pursued, including high-incidence tumors, and aims to submit additional regulatory applications in the coming years [8][41]. - Other innovative products in the pipeline, such as HER2 ADC and EGFR/HER3 dual-target antibodies, are also under development and could significantly contribute to future revenue [8][11]. Valuation and Market Potential - The target market capitalization for the company is set at 159.4 billion yuan, indicating a 13% upside potential from the current market value [9]. - The report emphasizes that the current market valuation does not fully reflect the potential of the company's diverse pipeline, suggesting further upside as clinical data emerges [11].

Core Viewpoint - Suzhou Xinnowei Pharmaceutical Technology Co., Ltd. has submitted its IPO application to the Sci-Tech Innovation Board, showcasing a rich pipeline of innovative drugs targeting major diseases, despite being an unprofitable company with significant accumulated losses [1][2][3]. Group 1: Company Overview - Xinnowei's innovative drug pipeline includes a drug application under review, three drugs in Phase III clinical trials, and multiple early-stage candidates, forming a "1+3+N" structure [1]. - The company is focusing on developing drugs for oncology and anti-infection, with key products like XNW5004, an EZH2 inhibitor, targeting various cancers [2][3]. Group 2: Financial Performance - Xinnowei has reported significant losses, with net profits of -463 million yuan, -427 million yuan, -386 million yuan, and -374 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively [3]. - The total accumulated losses amount to 2.026 billion yuan as of the reporting period [3]. Group 3: Market Competition - The company faces competition from both global pharmaceutical giants and domestic companies, with several similar products either already approved or in development [3]. - In the EZH2 inhibitor space, there are currently three approved drugs and nine in clinical development globally, indicating a competitive landscape [3]. Group 4: IPO Details - Xinnowei is applying for listing under the fifth set of standards on the Sci-Tech Innovation Board, aiming for a market valuation of over 4 billion yuan and plans to raise 2.94 billion yuan, with 2.34 billion yuan allocated for drug development [3]. Group 5: Legal Issues - The company is currently involved in ongoing intellectual property litigation, which may not directly impact its drug pipeline but could affect its reputation and financial standing [5][6]. - The lawsuit involves claims of trade secret infringement, with potential damages sought amounting to 50 million yuan [5].

（文章来源：证券日报） 证券日报网讯 12月24日，润都股份在互动平台回答投资者提问时表示，公司1类创新药盐酸去甲乌药碱 注射液（规格：2ml：2.5mg）及其原料药的注册审评工作正在有序推进中。公司已完成药学补充研究 并于2025年4月提交资料（此次发补，无临床相关内容）。根据《国家药品监督管理局药品审评过程中 审评计时中止与恢复管理规范（试行）》（药审业〔2022〕614号）规定，药品审评存在多种审评计时 中止情形，中止期间所占时间不计入审评时限。当前该药品处于药学审评序列暂停阶段，属于审评流程 中的正常情况。后续如有重大进展，公司将严格遵循信息披露规定及时履行披露义务。 ...

Group 1 - The company, along with several partners, has established a partnership agreement to form a new enterprise with an initial investment of RMB 227.27 million [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership will prioritize investments in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership will enable deep participation in the research and development of innovative drug pipelines, allowing the company to standardize and modularize its digital pharmaceutical R&D solutions [2] - The partnership will hold pipeline rights and participate in early clinical trials, aiming to capture key segments of the industry value chain while avoiding the complexities and long-term risks associated with traditional equity investments [2] - The company anticipates efficient exits through the transfer or sale of pipeline rights, facilitating rapid capital turnover and value realization [2]

董事会相信，通过成立合伙企业公司可以深度参与创新药管线研究及开发，公司将能够将其数智化医药 研发解决方案标准化、模块化地输出给各个处于早期至成长阶段的创新药研发管线，从而有机会分享药 物研发成功的超额收益以及扩大公司的行业足迹；其次，通过合伙企业持有管线权益，参与早期临床试 验抢占行业价值链关键环节，避免传统股权投资的复杂性与长周期风险，通过转让或出售管线实现高效 退出，实现了资金的快速周转和价值兑现。 格隆汇12月24日丨太美医疗科技(02576.HK)公告，于2025年12月24日，公司(作为有限合伙人)、太美智 研(作为有限合伙人)、嘉兴产投(作为有限合伙人)、陆高峰(作为有限合伙人)、陆海啸(作为有限合伙 人)、陈国娟(作为有限合伙人)及凯风太美(作为普通合伙人)订立合伙企业协议，内容有关成立合伙企 业。所有合伙人向合伙企业的初始注资总额将为人民币22,727万元，其中公司、太美智研、嘉兴产投、 陆高峰、陆海啸、陈国娟、及凯风太美将分别注资人民币7,000万元、人民币3,000万元、人民币10,000 万元、人民币1,000万元、人民币500万元、人民币1,000万元及人民币227万元。 合伙企业的业 ...

Core Viewpoint - Guoyuan International expects Nuo Cheng Jianhua (09969) to achieve revenues of RMB 2.01 billion, 2.06 billion, and 2.56 billion for the years 2025-2027, with net profits of RMB 117 million, 17 million, and 188 million respectively. The company holds approximately RMB 7.2 billion in cash and equivalents, sufficient for innovative research. The company is driven by scientific innovation and has strong product capabilities. A DCF model gives a target price of HKD 16.81, indicating a potential upside of 28% from the current price [1]. Group 1 - Acalabrutinib shows excellent performance in SLE IIb trials, with a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4%. In subgroups with baseline BILAG≥1A or ≥2B, the response rate improved by 35%, and in those with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, it improved by 43%. The CDE has approved the initiation of Phase III clinical trials for Acalabrutinib in SLE, with the first patient expected to be enrolled in Q1 2026 [2]. Group 2 - The company has accelerated its product pipeline, with the new TYK2 inhibitor ICP-488 approved for Phase II clinical trials for cutaneous lupus erythematosus (CLE). ICP-488 specifically binds to the TYK2 JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons. The NMPA has approved the company's Entrectinib (ICP-723) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors, showing high objective response rates (89.1%) and disease control rates (96.4%), with a 24-month PFS of 77.4% and OS of 90.8%, outperforming first-generation TRK inhibitors. Acalabrutinib's Phase III registration trial for immune thrombocytopenia (ITP) in China has completed patient enrollment, with plans to submit a new drug application in H1 2026 [3]. Group 3 - The company has made significant progress in business development, reaching an agreement with ZenasBio Pharma in October 2025. Zenas has been granted rights for Acalabrutinib for non-oncology indications outside Greater China and Southeast Asia, as well as global rights for multiple sclerosis; IL-17i rights are granted for regions outside Greater China and Southeast Asia, and global rights for CNS TYK2i. Zenas will pay a cash upfront of USD 100 million, with the total potential value of the deal exceeding USD 2 billion, which will significantly accelerate the overseas clinical development of products [4].

公司深度研究 | 健康元 呼吸龙头再起航，创新+国际化开启成长新篇章 健康元（600380.SH）首次覆盖报告 大型综合医药集团，创新+国际化开启新篇章。公司始创于 1992 年，保健品 业务起家，通过收并购不断开拓商业版图，经过 30 余年逐步发展为大型综 合医药集团。近年来，公司加快布局国际化及创新转型，一方面推动海外生 产基地建设，同时通过合作引进等方式快速丰富研发管线，聚焦呼吸常见疾 病，同时拓展镇痛、抗感染等领域布局。 制剂集采压力出清，新品放量助力主业拐点向上。近年来受艾普拉唑系列产 品、盐酸左沙丁胺醇吸入溶液等大单品降价影响，公司主业短暂承压，目前 核心产品降价压力基本出清，后续随着妥布霉素吸入溶液、玛帕西沙韦等新 品陆续放量，公司主业有望拐点向上。 加快创新管线布局，聚焦呼吸大适应症。多年深耕呼吸领域，近年来随着公 司创新转型进程加速推进，公司通过合作引进快速扩充在研管线，覆盖支气 管扩张、流感、COPD 等呼吸常见适应症。目前改良新药妥布霉素吸入溶液 以及流感新药玛帕西沙韦胶囊已获批，另外 TSLP 单抗、MABA 双靶点吸入 溶液、PREP 抑制剂等核心药物已进入 2 期临床。 丽珠集团： ...